These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. A pragmatic approach to the design of population pharmacokinetic studies. Roy A; Ette EI AAPS J; 2005 Oct; 7(2):E408-20. PubMed ID: 16353920 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic comparison of amlodipine adipate/valsartan fixed-dose combination with amlodipine besylate/valsartan fixed-dose combination in healthy volunteers. Nam JH; Oh M; Kim HJ; Han SK; Kim EJ; Song GS; Kim EY; Shin JG; Ghim JL; Kim HS Int J Clin Pharmacol Ther; 2015 Jan; 53(1):66-74. PubMed ID: 25034618 [TBL] [Abstract][Full Text] [Related]
9. Checking distributional assumptions for pharmacokinetic summary statistics based on simulations with compartmental models. Shen M; Russek-Cohen E; Slud EV J Biopharm Stat; 2017; 27(5):756-772. PubMed ID: 27669105 [TBL] [Abstract][Full Text] [Related]
10. Comparing sampling methods for pharmacokinetic studies using model averaged derived parameters. Barnett HY; Geys H; Jacobs T; Jaki T Stat Med; 2017 Nov; 36(27):4301-4315. PubMed ID: 28786135 [TBL] [Abstract][Full Text] [Related]
11. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development. Gieschke R; Steimer JL Eur J Drug Metab Pharmacokinet; 2000; 25(1):49-58. PubMed ID: 11032091 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and bioequivalence study of irbesartan tablets after a single oral dose of 300 mg in healthy Thai volunteers. Wittayalertpanya S; Chariyavilaskul P; Prompila N; Sayankuldilok N; Eiamart W Int J Clin Pharmacol Ther; 2014 May; 52(5):431-6. PubMed ID: 24725445 [TBL] [Abstract][Full Text] [Related]
13. Comparisons of the pharmacokinetics and tolerability of fixed-dose combinations of amlodipine besylate/losartan and amlodipine camsylate/losartan in healthy subjects: a randomized, open-label, single-dose, two-period, two-sequence crossover study. Choi Y; Lee S; Cho SM; Kang WH; Nam KY; Jang IJ; Yu KS Drug Des Devel Ther; 2016; 10():3021-3028. PubMed ID: 27703330 [TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects. Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510 [TBL] [Abstract][Full Text] [Related]
15. Effects of UGT1A1 Polymorphism, Gender and Triglyceride on the Pharmacokinetics of Telmisartan in Chinese Patients with Hypertension: A Population Pharmacokinetic Analysis. Huang L; Yang L; Huang J; Tan HY; Liu SK; Guo CX; Zuo XC; Yang GP; Pei Q Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):797-806. PubMed ID: 31254178 [TBL] [Abstract][Full Text] [Related]
16. Estimation of the area under a curve via several B-spline-based regression methods and applications. Tian M; Yu J; Kim J J Biopharm Stat; 2020 Jul; 30(4):704-720. PubMed ID: 32129135 [TBL] [Abstract][Full Text] [Related]
17. Power estimation using a population pharmacokinetics model with optimal design by clinical trial simulations: application in pharmacokinetic drug-drug interaction studies. Yang S; Beerahee M Eur J Clin Pharmacol; 2011 Mar; 67(3):225-33. PubMed ID: 21125264 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of olmesartan medoxomil in hemodialysis patients: little effect of dialysis upon its pharmacokinetics. Tanaka H; Nagasawa Y; Matsui I; Hamano T; Iwatani H; Kawada N; Horio M; Ito T; Isaka Y; Imai E Clin Exp Nephrol; 2009 Feb; 13(1):61-5. PubMed ID: 18574553 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of angiotensin II receptor blockers in the dog following a single oral administration. Baek IH; Lee BY; Lee ES; Kwon KI Drug Res (Stuttg); 2013 Jul; 63(7):357-61. PubMed ID: 23539423 [TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic modelling of S-warfarin to evaluate the design of drug-drug interaction studies for CYP2C9. Klein K; Gueorguieva I; Aarons L J Pharmacokinet Pharmacodyn; 2012 Apr; 39(2):147-60. PubMed ID: 22270321 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]